logo

For the Inventor, By the Inventor

Valby, Denmark

Søren Christensen

This inventor holds 19 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Monoclonal Antibodies. Top assignees: H. Lundbeck A/s, National Institute of Health and Medical Research, Université Paris Diderot-Paris 7. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Søren Christensen. Retrieved from https://idiyas.com/inventor/søren-christensen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 89.5

 

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 63(Granted Patents)


Location History:

  • Jyllinge, DK (2016 - 2019)
  • Valby, DK (2019 - 2023)

Company Filing History:

goldMedal18 out of 513 
 
H. Lundbeck A/s
 patents
silverMedal1 out of 1,853 
 
National Institute of Health and Medical Research
 patents
bronzeMedal1 out of 111 
 
Université Paris Diderot-Paris 7
 patents
where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-Sortilin Antibodies
Hyperphosphorylated Tau
Immunological Treatment
Cerebral Autosomal Dominant Arteriopathy
Pyroglutamated Aβ
Antibody Specificity
Therapeutic Agents
Neurodegenerative Disorders
19 patents (USPTO):Explore Patents
1. 12747294 - ANTI-SORTILIN ANTIBODIES AND USE THEREOF (2026-09-29),
2. 12331123 - Agent, uses and methods for treatment (2025-06-17),
3. 12129289 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2024-10-29),
4. 11739140 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2023-08-29),
5. 11548950 - Agent, uses and methods for treatment (2023-01-10),
6. 11111290 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2021-09-07),
7. 10934348 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2021-03-02),
8. 10894833 - Agents, uses and methods for treatment (2021-01-19),
9. 10889650 - Agent, uses and methods for treatment (2021-01-12),
10. 10647762 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2020-05-12),
11. 10562962 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2020-02-18),
12. 10487142 - Antibodies specific for hyperphosphorylated tau and methods of use thereof (2019-11-26),
13. 10479835 - Agent, uses and methods for treatment (2019-11-19),
14. 10472415 - Antibodies specific for hyperphosphorylated tau and methods of use (2019-11-12),
15. 10472414 - Antibodies specific to pyroglutamated Aβ (2019-11-12),

Title: Søren Christensen - The Innovative Inventor from Valby

Introduction: Søren Christensen is a renowned inventor hailing from Valby, Denmark, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Søren Christensen holds several patents in the areas of renewable energy technologies, sustainable agriculture solutions, and advanced medical devices, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Søren Christensen has worked with leading research institutions and universities to develop cutting-edge technologies that have revolutionized their respective industries.

Collaborations: Throughout his career, Søren Christensen has collaborated with top companies, banks, and research institutions to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Søren Christensen's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, making him a key figure in the world of technological advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…